Viralytics’ Oncolytic Immunotherapy technology is protected by a large family of patents worldwide – including patents granted in Europe and USA. These provide Viralytics with the exclusive and legally enforceable right to market and manufacture its technology globally.
Viralytics’ research and development program focuses on building and protecting its Intellectual Property base. The Company monitors new patents and patent applications worldwide.
The Company’s international granted patents and patent applications are listed below.
Summary of Patents and Patent Applications as at 5 October 2016
& PCT Publication Number
|Patents Granted||Applications Pending|
|A method of treating a malignancy in a subject and a pharmaceutical composition for use in same||25 November 1999
|Australia, Australia (Div1), Canada, Europe, Europe (Div1), Japan, New Zealand, USA, USA (Div1)||USA (Div2)|
|A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis||18 December 2002
|Australia, Canada, China, China (Div1), Europe, India, Hong Kong, Hong Kong (Div1), New Zealand, Singapore, South Africa, South Korea, USA|
|Modified oncolytic viruses||11 March 2004
|Australia, South Africa, USA|
|Methods and compositions for treatment of hematologic cancers||20 August 2004
|Australia, Canada, China, Hong Kong, Japan, Singapore, South Africa, South Korea, USA||Europe|
|Method and composition for treatment of neoplasms||17 Jan 2005
|China, Hong Kong|
|Methods for the treatment of bladder cancer||17 June 2013
|Australia, Canada, USA|
|Combination method for treatment of cancer||27 February 2014
|Australia, Canada, China, Europe, Japan, New Zealand, Singapore, South Korea, USA|